All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-09-21T08:07:30.000Z

Safety and efficacy of oral azacitidine (CC-486) plus R-CHOP in patients with previously untreated intermediate- to high-risk DLBCL: A phase I study

Sep 21, 2021
Share:

Bookmark this article

The combination of rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) has improved outcomes for patients with diffuse large B-cell lymphoma (DLBCL). However, some patient subgroups still have a poor prognosis due to resistance to R-CHOP chemotherapy. Recently, hypomethylating agents (HMAs) have been shown to reprogram the phenotype of cancer cells, generating new vulnerabilities that can be therapeutically explored. Oral azacitidine (oral-AZA; CC-486) is one such HMA that has been approved by both the U.S. Food and Drug Administration (FDA) and the European Commission as a maintenance therapy in adult patients with acute myeloid leukemia (AML). Oral-AZA has the potential to improve R-CHOP by enabling continuous low-dose administration over longer periods of time, potentially boosting epigenetic effects.

Martin et al.1 recently published in Blood a phase I study of CC-486 in combination with R-CHOP in patients with previously untreated DLBCL, Grade 3B follicular lymphoma (FL), or transformed lymphoma (TL).

Study design

This was a phase I, multicenter, open-label, dose-escalation study of CC-486 plus R-CHOP in patients with previously untreated intermediate- to high-risk DLBCL, Grade 3B FL, or TL. Eligible patients were aged 18−80 years, with measurable disease > 1.5 cm, Ann Arbor Stage II−IV disease, an International Prognostic Index (IPI) score of ≥2 or DLBCL double-positive for BCL2 and MYC, and an Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

  • The primary aim was to determine the safety and the maximum tolerated dose (MTD) of CC-486 in combination with R-CHOP.
  • Secondary aims included characterizing the pharmacokinetics (PK) of CC-486 and preliminary efficacy based on International Working Group (IWG) criteria.

The treatment schedule comprised six 21-day cycles of CC-486 evaluated at escalating doses of 100, 150, 200, or 300 mg. CC-486 was administered orally once daily for 7 days as a priming regimen (Figure 1) prior to initiation of R-CHOP on Day 1 of Cycle 1; thereafter, CC-486 was administered daily for 14 days during Cycles 1−5 of R-CHOP.

Figure 1. Treatment schedule* 

D, day; R-CHOP; rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone; RPD2, recommended phase 2 dose.
*Adapted from Martin et al1
CC-486 doses of 100, 150, 200, or 300 mg given 7 days before cycle 1 and on days 8-21 of cycles 1-5.
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone; growth factor was administered a minimum of 5 days before the start of CC-486 for pegfilgrastim, and up to 24 hours before the start of CC-486 for lenograstim or filgrastim. 

Results

Baseline characteristics

Fifty-nine patients (33 in the dose-escalation phase and 26 in the dose-expansion phase) were enrolled, and all but one patient had DLBCL; the remaining patient had Grade 3B FL. The median age was 66 years (range, 25−80) and 76% of patients were aged ≥60 years; 59% of the patients were male. The baseline characteristics are listed in Table 1.

  • A total of 88% of patients treated in both dose-escalation and expansion phases completed all cycles of CC-486, while 92% completed six cycles of R-CHOP.
  • The mean relative dose intensity (RDI) of CC-486 was 76% and 82% in patients treated with CC-486 200 and 300 mg doses, respectively. The mean RDI of R-CHOP was similar in patients treated with CC-486 200 mg (96%) and 300 mg (96%).
  • The overall mean RDI of CC-486 plus R-CHOP was 90%, with 70% of patients having an RDI > 85%.

Table 1. Baseline characteristics*

Characteristic, % unless otherwise stated

ESCAL

EXP

ESCAL + EXP

Overall
(n = 33)

RP2D 300 mg
(n = 26)

RP2D 300 mg
(n = 40)

Overall
(N = 59)

ECOG PS

              0

52

46

53

49

              1

42

50

45

46

Ann Arbor disease stage

              II

6

8

5

7

              III

30

31

33

31

              IV

64

62

63

63

Median time between first diagnosis and first dose (range), days

28 (7−380)

27 (3−103)

28 (3−380)

28 (3−380)

DLBCL

27 (9−61)

25 (3−103)

24 (3−103)

26 (3−103)

IPI score

              Low/low-intermediate (=2)

46

35

45

41

              High-intermediate/high (≥3)

55

65

55

59

Transformed DLBCL

15

19

20

17

Cell of origin§

              GCB

39

46

40

42

              Non-GCB

27

35

35

31

              Undetermined

33

19

25

27

Overexpression of BCL2 and/or MYCǁ

66

92

84

78

Molecular abnormalities

45

57

57

50

DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; ESCAL, dose-escalation phase; EXP, expansion phase; GCB, germinal center B cell; IPI, International Prognostic Index; RP2D, recommended phase 2 dose.
*Adapted from Martin et al1
Total number of patients with DLBCL (not transformed follicular lymphoma) was 49 (ESCAL, n = 28; EXP, n = 21; RP2D 300 mg, n = 32).
Includes one patient with an IPI score of 0/1 (low) and 23 patients with an IPI score of 2 (low-intermediate.)
§Hans algorithm.
ǁOverexpression of BCL2 (≥ 30%) or MYC (≥ 40%) was determined by immunohistochemistry based on local pathology laboratory assessment.

Safety

  • Treatment-emergent adverse events (TEAEs) were observed in all patients, most commonly nausea (66%), neutropenia (63%), and constipation (58%).
  • Grade 3 or 4 TEAEs were mostly hematologic, including neutropenia (63%), febrile neutropenia (25%), anemia (17%), and thrombocytopenia (14%).
  • The incidence of TEAEs declined over the course of the study, with most events occurring during Cycles 1 or 2 (98% and 93% of patients, respectively).
  • Serious adverse events (SAEs) were observed in 39% of patients, most commonly febrile neutropenia (24%).
  • No dose-related toxicity (DLT) was observed at 100 and 150 mg of CC-486. Two patients developed DLT (Grade 4 neutropenia and Grade 4 prolonged neutropenia) at 300 mg.
  • Although MTD was not attained, 300 mg was established as the recommended phase 2 dose (RP2D).

Efficacy

  • The overall response rate (ORR) was 95%, with 88% of patients attaining complete response (CR) at the 300 mg dose level (Table 2).
  • Response rates were similar for patients with IPI scores of 2 and ≥3, with an ORR of 96% and CR in 22 patients (92%) with an IPI of 2, and an ORR of 94% and CR in 30 patients (86%) with an IPI ≥3.
  • At a median follow-up of 29 months, the 1- and 2-year progression-free survival (PFS) rates for the overall population were 84% and 79%, respectively (Table 2).

Table 2. Efficacy by treatment phase*

Responses, % unless otherwise stated

ESCAL

EXP

ESCAL + EXP

Overall
(n = 33)

RP2D 300 mg
(n = 26)

RP2D 300 mg
(n = 26)

Overall
(N = 59)

ORR, (95% CI)

97 (84−100)

92 (75−99)

95 (83−99)

95 (86−99)

CR

91

85

88

88

PR

6

8

8

7

SD

3

4

3

3

Median time to response, months

2

2

2

2

PFS rate at 1 year

97

69

78

84

PFS rate at 2 years

90

65

72

79

CR, complete response; CI, confidence interval; ESCAL, dose-escalation phase; EXP, expansion phase; ORR, overall response rate; PR, partial response; PFS, progression-free survival; RP2D, recommended phase 2 dose; SD, stable disease.
*Adapted from Martin et al1
Overall responders only.

Pharmacokinetics

  • CC-486 plasma exposure demonstrated a dose-proportional increase at the 100 and 300 mg dose levels.
  • The terminal half-life of CC-486 alone and in combination with R-CHOP was 0.3−0.6 hours and the plasma clearance ranged from 812−2,335 L/hour.

Conclusion

This prospective study demonstrated that CC-486 plus R-CHOP can be administered safely to patients with previously untreated intermediate- to high-risk DLBCL, Grade 3B FL, and TL. The ORR and CR rates were similar regardless of IPI scores, cell of origin and transformation origin. Future studies are warranted to explore the evaluation of DLTs early in therapy. A prospective phase II/III trial (Southwest Oncology Group/SWOG) evaluating CC-486 plus rituximab and reduced dose of CHOP in elderly patients with DLBCL is currently underway.

  1. Martin P, Bartlett NL, Chavez JC, et al. Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood. 2021;blood.2021011679. DOI: 1182/blood.2021011679

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox